Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
South Korea
· Delayed Price · Currency is KRW 153,600
+3,800 (2.54%)
Apr 18, 2025, 3:30 PM KST
Sam Chun Dang Pharm. Revenue
In the year 2024, Sam Chun Dang Pharm. had annual revenue of 210.92B KRW with 9.47% growth. Sam Chun Dang Pharm. had revenue of 55.19B in the quarter ending December 31, 2024, with 5.15% growth.
Revenue
210.92B
Revenue Growth
+9.47%
P/S Ratio
16.94
Revenue / Employee
515.71M
Employees
409
Market Cap
3,572.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 210.92B | 18.26B | 9.47% |
| Dec 31, 2023 | 192.67B | 15.33B | 8.65% |
| Dec 31, 2022 | 177.34B | 10.06B | 6.01% |
| Dec 31, 2021 | 167.27B | 412.57M | 0.25% |
| Dec 31, 2020 | 166.86B | -19.74B | -10.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| Peptron | 3.15B |
| LigaChem Biosciences | 125.90B |